Navin Fluorine Q2 FY27 profit rose 81% across businesses

Navin Fluorine International Limited reported Q2 FY27 profit after tax of Rs 269 crore, up 81% year on year, as operating revenue rose 57% to Rs 1,191 crore. Management attributed the quarter’s outcome to refrigerant pricing and volumes, specialty-plant efficiency, and contract manufacturing qualification campaigns across its three businesses.

How much did Navin Fluorine's Q2 FY27 profit increase?

Navin Fluorine's Q2 FY27 profit after tax increased 81% year on year to Rs 269 crore, while operating profit before tax rose 87% to Rs 336 crore. Consolidated operating revenue reached Rs 1,191 crore, a 57% increase, and operating earnings before interest, taxes, depreciation and amortisation, or EBITDA, grew 66% to Rs 407 crore. Profit growth therefore outpaced revenue growth in the quarter.

Navin Fluorine reported an operating EBITDA margin of 34.2% in Q2 FY27. Management said all three business verticals performed well and cited foreign-exchange tailwinds, pricing actions, operating leverage and operating-efficiency measures as factors that offset sourcing-cost impacts. These mechanisms were cited for both year-on-year and quarter-on-quarter performance, rather than a single exceptional contract or plant contribution.

What drove Navin Fluorine's sequential growth across businesses?

Navin Fluorine said sequential growth in its high-performance products business came from improved refrigerant-gas pricing, higher volumes at its anhydrous hydrogen fluoride, or AHF, facility, and growth in the Orchid HFO business. Management said realised prices had improved even where market averages appeared stable, while increased AHF utilisation supported volumes during Q2 FY27.

In specialty chemicals, Navin Fluorine said it was extracting more output from existing multipurpose plants, or MPPs, through product mapping, fewer production steps and research-and-development work. Management said MPP-1 and MPP-2 were expected to exceed their internally cited PAR level by the end of FY27. The company commissioned Dahej MPP debottlenecking in September 2026, and management said that added capacity was not included in the reported Q2 numbers.

Navin Fluorine said its contract development and manufacturing organisation, or CDMO, business grew through base business from Fermion and new qualification campaigns. Management also cited favourable trial developments for existing molecules and rising demand for an existing molecule from a European CDMO customer. It said the business was within reach of its US$100 million order-book visibility target for FY27, without disclosing quarter-specific CDMO revenue.

How did Navin Fluorine's first-half FY27 earnings compare?

Navin Fluorine's first-half FY27 profit after tax rose 93% year on year to Rs 513 crore, compared with a 51% increase in operating revenue to Rs 2,236 crore. Operating EBITDA increased 69% to Rs 765 crore, and the operating EBITDA margin expanded 367 basis points to 34.2%. A basis point is one-hundredth of a percentage point, making the reported expansion 3.67 percentage points.

Operating profit before tax increased from Rs 320 crore in the first half of FY26 to Rs 619 crore in the first half of FY27, a 93% rise. Navin Fluorine reported earnings per share of Rs 100 and net operating working-capital days of 72 days for H1 FY27. Management said the working-capital measure remained within its financial framework.

Which projects could add to Navin Fluorine's future output?

Navin Fluorine said its R32 capacity expansion was on track for commissioning shortly as of the October 30, 2026 earnings call. Management expected some incremental contribution toward the end of the then-current quarter, followed by a possible fuller ramp-up in the subsequent quarter. R32 is a refrigerant product within the high-performance products business.

Navin Fluorine also said the Chemours project was progressing toward commissioning in Q3 FY27. Management described the timing change as a conscious decision with Chemours to select the right process for the initial capacity, which could support a larger installation if demand develops. It said orders for future quarters were already in place when the project approached commissioning.

In CDMO, Navin Fluorine expects Phase 2 of the cGMP-4 facility, involving approximately Rs 125 crore of capital expenditure, to become operational by the end of Q4 FY27. Management said both cGMP-4 phases are dedicated to Fermion and that it would consider cGMP-5 when good manufacturing practice plant utilisation reaches 70% to 80%. Advanced-material adoption capacity remains targeted for commissioning by Q2 FY28.

What does the Solstice contract extension change for Navin Fluorine?

Navin Fluorine said the HFO supply contract with Solstice Advanced Materials was extended by four years until December 2032, adding approximately US$180 million of potential revenue. Management said the extension changes the arrangement from a seven-year contract to an 11-year contract and gives longer visibility from the same asset base.

Management cautioned against calculating a simple annual revenue run rate from the US$180 million potential because the contracts contain pass-through pricing mechanisms and different commercial terms after capital expenditure is recovered. It said the extension guarantees larger volumes than under the prior arrangement. Management also said Navin Fluorine can pursue other HFO varieties where they do not conflict with the contract.

Conclusion

Navin Fluorine’s Q2 and H1 FY27 results show revenue and profit growth across high-performance products, specialty chemicals and CDMO. Q2 profit after tax rose 81% to Rs 269 crore, while H1 profit after tax rose 93% to Rs 513 crore, supported by refrigerant realisations, improved AHF utilisation, greater MPP efficiency and CDMO qualification activity.

The next disclosed execution points are the R32 ramp-up after its planned commissioning, Chemours project commissioning in Q3 FY27, and cGMP-4 Phase 2 becoming operational by the end of Q4 FY27. Management also said the September 2026 Dahej MPP debottlenecking had not contributed to Q2 FY27, making later specialty-chemical output a relevant measure of delivery.